Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Skin fluid may hold key to early heart disease detection

NCT ID NCT06632353

Diagnosis Sponsor: Ascilion AB Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study explores whether fluid from the skin can be used to detect signs of heart disease. Researchers will collect skin fluid and blood samples from 30 volunteers, including older adults with heart failure and younger healthy adults. The goal is to see if certain biomarkers in skin fluid can help diagnose or monitor cardiovascular conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple skin test for early detection of heart disease, potentially allowing for earlier treatment.
What could go wrong
This is a very small, early-stage study focused on measuring biomarkers, not treating disease. It may not find reliable markers or translate into a practical test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy volunteers and subjects recruited at hospital

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: Group 1: Chronic heart failure with stable therapy. NYHA classification II, III and IV. Age \> 60 years. Group 2: Age 18-40 years. Exclusion criteria: * Participating in another clinical investigation which may affect the study outcome according to clinical judgement. * Previous use of sampling system used. * Pregnancy or lactating. * Any disease or condition that may be affected. * Individuals who lack the ability to fully consent to participate in the study. * Severe skin injury. * Tattoo or piercing close to sampling area. * Group 1: All forms of emergency care. * Group 1: Non-stable therapy. * Group 1: Sepsis. * Group 1: BMI \> 30kg/m2. * Group 1: Age \> 84 years. * Group 2: Known heart or vascular disease. * Group 2: Diabetes. * Group 2: Kidney disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder congestive heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases

Contacts and locations

Locations

  • Danderyd Hospital

    Danderyd, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.